The adapted Zelen was a feasible design to trial exercise in myeloma survivors.
Exercise
Exercise-oncology
Multiple myeloma
Physical activity
Post randomization consent
Research design
Journal
Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
07
08
2019
revised:
04
03
2020
accepted:
07
04
2020
pubmed:
15
4
2020
medline:
5
3
2021
entrez:
15
4
2020
Statut:
ppublish
Résumé
We used a method rarely seen in cancer behavioral trials to explore methods of overcoming difficulties often seen in randomized controlled trials. We report our experiences of the adapted Zelen design, so that other researchers can consider this approach for behavioral trials. The adapted Zelen design was used to explore the effects of exercise on multiple myeloma patients fatigue, quality of life, and physical outcomes. All participants consented to an observational cohort study of lifestyle factors but were unaware of subsequent randomization to remain in cohort only group or be offered an exercise intervention requiring second consent. There was lower than expected uptake to the exercise offered group (57%), so the length of recruitment increased from 24 to 29 months to ensure power was reached. At enrollment, patients were unaware of the potential increased commitment, and as a result, 62% of participants allocated to the intervention declined because of the extra time/travel commitment required. This emulates clinical settings and suggests improvements in intervention delivery are required. Our findings suggest that the adapted Zelen design may be useful in limiting dropout of controls due to dissatisfaction from group allocation, or contamination of control arm. Future use of this design warrants careful consideration of the study resources and recruitment time frames required but holds potential value in reducing contamination, control group dissatisfaction, and resulting dropout. Adapted Zelen design reduces selection bias and therefore gives clinicians a better understanding of acceptability in clinical settings. Future studies should evaluate control group experiences of the design and formally record contamination throughout the study to confirm its acceptability.
Identifiants
pubmed: 32289352
pii: S0895-4356(19)30602-X
doi: 10.1016/j.jclinepi.2020.04.004
pmc: PMC7482584
pii:
doi:
Types de publication
Clinical Trial
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-83Subventions
Organisme : Cancer Research UK
ID : 14133
Pays : United Kingdom
Organisme : Department of Health
ID : ICA-CDRF-2017-03-067
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1418/A14133
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 28960542
J Gen Intern Med. 2016 Dec;31(12):1511-1518
pubmed: 27384536
Cancer Treat Rev. 2009 Jun;35(4):383-90
pubmed: 19131171
Soc Sci Med. 2002 Sep;55(5):709-19
pubmed: 12190265
J Clin Epidemiol. 2019 Sep;113:137-146
pubmed: 31146022
J Clin Epidemiol. 2012 Mar;65(3):288-92
pubmed: 21856119
Cancer Nurs. 2017 Sep/Oct;40(5):E1-E8
pubmed: 27532741
J Clin Epidemiol. 1999 Jun;52(6):503-7
pubmed: 10408988
Contemp Clin Trials. 2006 Aug;27(4):305-19
pubmed: 16455306
PLoS One. 2015 Mar 27;10(3):e0120996
pubmed: 25815479
BMC Hematol. 2013 Oct 31;13(1):9
pubmed: 24238148
N Engl J Med. 1979 May 31;300(22):1242-5
pubmed: 431682
BMJ. 2012 Jan 30;344:e70
pubmed: 22294757
J Cancer Surviv. 2010 Jun;4(2):87-100
pubmed: 20052559
Control Clin Trials. 1999 Apr;20(2):149-71
pubmed: 10227415
Contemp Clin Trials. 2006 Aug;27(4):320-32
pubmed: 16388991
Eur J Cancer Care (Engl). 2003 Dec;12(4):347-57
pubmed: 14982314
Br J Gen Pract. 2012 Jan;62(594):10-1
pubmed: 22520661
BMC Cancer. 2013 Jan 24;13:31
pubmed: 23347597
J Health Serv Res Policy. 2005 Oct;10(4):220-5
pubmed: 16259688
BMC Cancer. 2016 Jul 04;16:387
pubmed: 27377407
Clin Trials. 2018 Feb;15(1):9-16
pubmed: 29224380
BMC Cancer. 2010 Jun 09;10:272
pubmed: 20534147
J Clin Epidemiol. 2010 Aug;63(8):900-6
pubmed: 20189770
Eur J Cancer Care (Engl). 2017 Jul;26(4):
pubmed: 28135016
JAMA. 2005 Mar 2;293(9):1089-99
pubmed: 15741531
J Med Ethics. 1998 Dec;24(6):401-8
pubmed: 9873981
BMJ Open. 2017 Oct 8;7(10):e018015
pubmed: 28993394